Amgen Inc header image

Amgen Inc

AMGN

Equity

ISIN null / Valor 907582

NASDAQ (2026-10-06)
USD 402.60-0.09%

Amgen Inc
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

Amgen Inc. is a global biopharmaceutical company based in Thousand Oaks, California, that discovers, develops, manufactures and markets protein- and antibody-based therapies for serious illnesses; its commercial portfolio and pipeline focus on areas such as oncology, hematology and supportive care, nephrology, bone disease, cardiovascular disease and inflammation, and it also participates in the biosimilars market. The company’s business model combines research and late-stage development of biologics with in-house manufacturing and global commercial operations, with well-known marketed products that have included Epogen and Neulasta (supporting hematologic indications), Enbrel (inflammatory disease), Repatha (cardiovascular risk) and Prolia/Xgeva (bone health). Amgen is publicly traded and derives the bulk of its revenue from therapeutic product sales while continuing to invest in R&D to replenish and expand its pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

36.9%1Y
50.5%3Y
91.7%5Y

Performance

27.4%1Y
26.4%3Y
24.3%5Y

Volatility

Market cap

217658 M

Market cap (USD)

Daily traded volume (Shares)

2,036,870

Daily traded volume (Shares)

1 day high/low

261.55 / 258.74

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.00
Nature:
starstarstarstarstar
3.00
Zoe Holloway
UK, 07 Feb 2026
star star star star star
Steady upwards trend
Kendra Ho
UK, 06 Feb 2026
star star star star star
Overall good performance

EQUITIES OF THE SAME SECTOR

IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.30%USD 259.98
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.01%USD 7.31
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 982352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.65%GBP 119.58
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1103058
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.70%GBP 10.12
Envista Holdings Corporation
Envista Holdings Corporation Envista Holdings Corporation Valor: 49153522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.30%USD 23.27
Humana Inc
Humana Inc Humana Inc Valor: 940174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%USD 404.27
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.60%GBP 16.20
Indivior PLC
Indivior PLC Indivior PLC Valor: 121550831
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.67%GBP 27.04
Beximco Pharmaceuticals Ltd
Beximco Pharmaceuticals Ltd Beximco Pharmaceuticals Ltd Valor: 2318407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.54
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.93%EUR 70.30